罗格列酮逆转Burkitt淋巴瘤raji细胞对紫杉醇耐药的作用及机制

目的研究罗格列酮(RGZ)逆转Burkitt淋巴瘤raji细胞对紫杉醇耐药的作用及机制。方法建立人Burkitt淋巴瘤raji紫杉醇耐药细胞株(raji/TAX 25),细胞计数法检测raji/TAX 25对TAX的耐药指数和RGZ处理后各组raji细胞的增殖活性。流式细胞仪检测凋亡率,蛋白质印迹法(western blot)检测raji细胞耐药基因P-gp和多药耐药相关蛋白(MRP)的变化。结果成功建立了raji/TAX 25耐药株、耐药指数为45.90,RGZ明显逆转Burkitt淋巴瘤raji细胞对紫杉醇的耐药性(P<0.01)。western blot检测发现raji细胞P-gp和MRP表达显著下降(P<0.05)。结论 RGZ具有逆转Burkitt淋巴瘤raji细胞对紫杉醇耐药的作用,其作用机制与下调P-gp和MRP表达有关。

Objective To study the effects and mechanism of Rosiglitazone （RGZ） reversed Burkitt lymphoma Raji cells paclitaxel resistance. Methods Established human Burkitt lymphoma Raji paclitaxel resistant cell lines （raji/TAX 25）. Cell counting was used to observe the raji/TAX 25 resistance index and the proliferation of raji cells deal with different concentrations of RGZ. Flow cytometry was used to measure the apoptosis rate. western was used to measure the expression of cell resistance gene P-gp and MRP. Results Successfully established raji/TAX 25 of drug-resistant strains, resistance index was 45.90, RGZ significantly reversed the Raji cells paclitaxel resistance （P〈0.01）. Decreased raji cells P-gp and MRP protein expression. Conclusion RGZ can reversed Burkitt lymphoma Raji cells paclitaxel resistance, its mechanism is related to inhibit P-gp and MRP protein protein expression.